Michael R. Migden, MDAcademic Affiliation: Departments of Dermatology and Head and Neck SurgeryThe University of Texas MD Anderson Cancer CenterHouston, TX, USADr. Migden, professor, departments of dermatology and head and neck surgery at MD Anderson Cancer Center, specializes in Mohs micrographic surgery, complex reconstruction, and clinical research in cutaneous oncology. He is the principal investigator of various clinical trials that evaluate the use of hedgehog pathway inhibitors and immunotherapy for advanced nonmelanoma skin cancer, devices for detection of cutaneous malignancy and methods for documenting skin biopsy site location for treatment. His research has been published in the New England Journal of Medicine, Lancet Oncology, and other high impact peer-reviewed journals.  Dr. Migden is the author of multiple book chapters and speaks nationally and internationally on cutaneous reconstruction, hedgehog pathway inhibitors, immunotherapy therapy, and the use of digital media in surgical education.Leon Chen, MDAcademic Affiliation: Department of DermatologyThe University of Texas McGovern Medical School at Houston,Houston, Texas, USADepartment of Dermatology The University of Texas MD Anderson Cancer CenterHouston, TX, USADr. Chen received his medical degree from the University of Texas McGovern Medical School at Houston and continued his fellowship training for Micrographic Surgery and Dermatologic Oncology (Mohs) at MD Anderson Cancer Center after completing dermatology residency at the MD Anderson Cancer Center/University of Texas McGovern Medical School combined program. Dr. Chen’s deep passion for cutaneous oncology has led him to author numerous research manuscripts, and his research has been presented at national and international dermatology meetings. His clinical interests include treating skin cancers with both surgical and non-surgical modalities.Sirunya Silapunt, MDAcademic Affiliation: Department of DermatologyThe University of Texas McGovern Medical School at Houston,Houston, Texas, USADr. Silapunt is a board-certified dermatologist and currently serves as an associate professor of the Department of Dermatology at The University of Texas McGovern Medical School at Houston. She is a faculty in Micrographic Surgery & Dermatologic Oncology Fellowship Program, clinical associate professor at MD Anderson Cancer Center, and an associate program director for the American Society of Dermatologic Surgery (ASDS) Cosmetic Dermatologic Surgery Fellowship Accreditation Program. Dr. Silapunt treats a wide variety of skin conditions and a large part of her practice consists of skin cancer and varicose vein treatments. Dr. Silapunt also has aspecial focus in laser and cosmetic dermatology. Dr. Silapunt has authored more than 50 peer-reviewed research manuscripts and numerous book chapters. She is an editor of the textbook “Treatment of Leg Veins, 2nd edition”. Dr. Silapunt’s academic achievement and expertise in the field of dermatology have made her an invited speaker at various national and international conferences.

• Chapter 1. Epidemiology and Risk Factors of Basal Cell Carcinoma.- Chapter 2. Pathophysiology of Basal Cell Carcinoma and Its Associated Genetic Syndromes.- Chapter 3. Histopathology of Basal Cell Carcinoma and Its Variants.- Chapter 4. Topical Therapy for the Treatment of Basal Cell Carcinoma.- Chapter 5. Local Immunotherapy for Basal Cell Carcinoma with Interferon.- Chapter 6. Cryotherapy and Electrodesiccation & Curettage for Basal Cell Carcinoma.- Chapter 7. Mohs Micrographic Surgery for the Treatment of Basal Cell Carcinoma.- Chapter 8. Surgical Treatment for Basal Cell Carcinoma of the Head and Neck.- Chapter 9. Special Considerations for Periocular Basal Cell Carcinoma.- Chapter 10. Radiotherapy for Basal Cell Carcinoma.- Chapter 11. Photodynamic Therapy for the Treatment of Basal Cell Carcinoma.- Chapter 12. Laser Therapy for the Treatment of Basal Cell Carcinoma.- Chapter 13. Hedgehog Signaling Pathway Inhibitors for Basal Cell Carcinoma.- Chapter 14. Immunotherapy for Basal Cell Carcinoma.- Chapter 15. Treatment: Future Directions.

Michael R. Migden, MDAcademic Affiliation: Departments of Dermatology and Head and Neck SurgeryThe University of Texas MD Anderson Cancer CenterHouston, TX, USADr. Migden, professor, departments of dermatology and head and neck surgery at MD Anderson Cancer Center, specializes in Mohs micrographic surgery, complex reconstruction, and clinical research in cutaneous oncology. He is the principal investigator of various clinical trials that evaluate the use of hedgehog pathway inhibitors and immunotherapy for advanced nonmelanoma skin cancer, devices for detection of cutaneous malignancy and methods for documenting skin biopsy site location for treatment. His research has been published in the New England Journal of Medicine, Lancet Oncology, and other high impact peer-reviewed journals.  Dr. Migden is the author of multiple book chapters and speaks nationally and internationally on cutaneous reconstruction, hedgehog pathway inhibitors, immunotherapy therapy, and the use of digital media in surgical education.Leon Chen, MDAcademic Affiliation: Department of DermatologyThe University of Texas McGovern Medical School at Houston,Houston, Texas, USADepartment of Dermatology The University of Texas MD Anderson Cancer CenterHouston, TX, USADr. Chen received his medical degree from the University of Texas McGovern Medical School at Houston and continued his fellowship training for Micrographic Surgery and Dermatologic Oncology (Mohs) at MD Anderson Cancer Center after completing dermatology residency at the MD Anderson Cancer Center/University of Texas McGovern Medical School combined program. Dr. Chen’s deep passion for cutaneous oncology has led him to author numerous research manuscripts, and his research has been presented at national and international dermatology meetings. His clinical interests include treating skin cancers with both surgical and non-surgical modalities.Sirunya Silapunt, MDAcademic Affiliation: Department of DermatologyThe University of Texas McGovern Medical School at Houston,Houston, Texas, USADr. Silapunt is a board-certified dermatologist and currently serves as an associate professor of the Department of Dermatology at The University of Texas McGovern Medical School at Houston. She is a faculty in Micrographic Surgery & Dermatologic Oncology Fellowship Program, clinical associate professor at MD Anderson Cancer Center, and an associate program director for the American Society of Dermatologic Surgery (ASDS) Cosmetic Dermatologic Surgery Fellowship Accreditation Program. Dr. Silapunt treats a wide variety of skin conditions and a large part of her practice consists of skin cancer and varicose vein treatments. Dr. Silapunt also has aspecial focus in laser and cosmetic dermatology. Dr. Silapunt has authored more than 50 peer-reviewed research manuscripts and numerous book chapters. She is an editor of the textbook “Treatment of Leg Veins, 2nd edition”. Dr. Silapunt’s academic achievement and expertise in the field of dermatology have made her an invited speaker at various national and international conferences.

• Chapter 1. Epidemiology and Risk Factors of Basal Cell Carcinoma.- Chapter 2. Pathophysiology of Basal Cell Carcinoma and Its Associated Genetic Syndromes.- Chapter 3. Histopathology of Basal Cell Carcinoma and Its Variants.- Chapter 4. Topical Therapy for the Treatment of Basal Cell Carcinoma.- Chapter 5. Local Immunotherapy for Basal Cell Carcinoma with Interferon.- Chapter 6. Cryotherapy and Electrodesiccation & Curettage for Basal Cell Carcinoma.- Chapter 7. Mohs Micrographic Surgery for the Treatment of Basal Cell Carcinoma.- Chapter 8. Surgical Treatment for Basal Cell Carcinoma of the Head and Neck.- Chapter 9. Special Considerations for Periocular Basal Cell Carcinoma.- Chapter 10. Radiotherapy for Basal Cell Carcinoma.- Chapter 11. Photodynamic Therapy for the Treatment of Basal Cell Carcinoma.- Chapter 12. Laser Therapy for the Treatment of Basal Cell Carcinoma.- Chapter 13. Hedgehog Signaling Pathway Inhibitors for Basal Cell Carcinoma.- Chapter 14. Immunotherapy for Basal Cell Carcinoma.- Chapter 15. Treatment: Future Directions.

Michael R. Migden, MDAcademic Affiliation: Departments of Dermatology and Head and Neck SurgeryThe University of Texas MD Anderson Cancer CenterHouston, TX, USADr. Migden, professor, departments of dermatology and head and neck surgery at MD Anderson Cancer Center, specializes in Mohs micrographic surgery, complex reconstruction, and clinical research in cutaneous oncology. He is the principal investigator of various clinical trials that evaluate the use of hedgehog pathway inhibitors and immunotherapy for advanced nonmelanoma skin cancer, devices for detection of cutaneous malignancy and methods for documenting skin biopsy site location for treatment. His research has been published in the New England Journal of Medicine, Lancet Oncology, and other high impact peer-reviewed journals.  Dr. Migden is the author of multiple book chapters and speaks nationally and internationally on cutaneous reconstruction, hedgehog pathway inhibitors, immunotherapy therapy, and the use of digital media in surgical education.Leon Chen, MDAcademic Affiliation: Department of DermatologyThe University of Texas McGovern Medical School at Houston,Houston, Texas, USADepartment of Dermatology The University of Texas MD Anderson Cancer CenterHouston, TX, USADr. Chen received his medical degree from the University of Texas McGovern Medical School at Houston and continued his fellowship training for Micrographic Surgery and Dermatologic Oncology (Mohs) at MD Anderson Cancer Center after completing dermatology residency at the MD Anderson Cancer Center/University of Texas McGovern Medical School combined program. Dr. Chen’s deep passion for cutaneous oncology has led him to author numerous research manuscripts, and his research has been presented at national and international dermatology meetings. His clinical interests include treating skin cancers with both surgical and non-surgical modalities.Sirunya Silapunt, MDAcademic Affiliation: Department of DermatologyThe University of Texas McGovern Medical School at Houston,Houston, Texas, USADr. Silapunt is a board-certified dermatologist and currently serves as an associate professor of the Department of Dermatology at The University of Texas McGovern Medical School at Houston. She is a faculty in Micrographic Surgery & Dermatologic Oncology Fellowship Program, clinical associate professor at MD Anderson Cancer Center, and an associate program director for the American Society of Dermatologic Surgery (ASDS) Cosmetic Dermatologic Surgery Fellowship Accreditation Program. Dr. Silapunt treats a wide variety of skin conditions and a large part of her practice consists of skin cancer and varicose vein treatments. Dr. Silapunt also has aspecial focus in laser and cosmetic dermatology. Dr. Silapunt has authored more than 50 peer-reviewed research manuscripts and numerous book chapters. She is an editor of the textbook “Treatment of Leg Veins, 2nd edition”. Dr. Silapunt’s academic achievement and expertise in the field of dermatology have made her an invited speaker at various national and international conferences.

• Chapter 1. Epidemiology and Risk Factors of Basal Cell Carcinoma.- Chapter 2. Pathophysiology of Basal Cell Carcinoma and Its Associated Genetic Syndromes.- Chapter 3. Histopathology of Basal Cell Carcinoma and Its Variants.- Chapter 4. Topical Therapy for the Treatment of Basal Cell Carcinoma.- Chapter 5. Local Immunotherapy for Basal Cell Carcinoma with Interferon.- Chapter 6. Cryotherapy and Electrodesiccation & Curettage for Basal Cell Carcinoma.- Chapter 7. Mohs Micrographic Surgery for the Treatment of Basal Cell Carcinoma.- Chapter 8. Surgical Treatment for Basal Cell Carcinoma of the Head and Neck.- Chapter 9. Special Considerations for Periocular Basal Cell Carcinoma.- Chapter 10. Radiotherapy for Basal Cell Carcinoma.- Chapter 11. Photodynamic Therapy for the Treatment of Basal Cell Carcinoma.- Chapter 12. Laser Therapy for the Treatment of Basal Cell Carcinoma.- Chapter 13. Hedgehog Signaling Pathway Inhibitors for Basal Cell Carcinoma.- Chapter 14. Immunotherapy for Basal Cell Carcinoma.- Chapter 15. Treatment: Future Directions.